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OBJECTIVES We examined whether endothelial dysfunction occurs when acute hyperglycemia is induced
by oral glucose loading.
BACKGROUND Endothelial dysfunction has been shown to occur in patients with diabetes mellitus (DM),
and chronic hyperglycemia is implicated as a cause of endothelial dysfunction. However, in
many patients with Type 2 DM and in those with impaired glucose tolerance (IGT), fasting
blood glucose may be within normal limits, and hyperglycemia occurred only post-prandially.
METHODS With ultrasound technique, we measured flow-mediated endothelium-dependent vasodila-
tion during oral glucose tolerance test in 58 subjects: (17 patients with normal glucose
tolerance [NGT], 24 with IGT, and 17 with type 2 DM). In addition, we measured the levels
of thiobarbituric acid reactive substances (TBARS) and nitrite/nitrate.
RESULTS Flow-mediated vasodilation decreased after glucose loading (NGT: 7.53 6 0.40, 4.24 6 0.28
and 6.35 6 0.40, in fasting, at 1- and 2-h, respectively, IGT: 6.50 6 0.48, 1.40 6 0.41** and
4.00 6 0.47*, respectively; DM: 4.77 6 0.37, 1.35 6 0.38** and 1.29 6 0.29%**, respectively;
*p , 0.01 vs. fasting, **p , 0.005 vs. fasting). The TBARS concentration increased in parallel
with plasma glucose level in each group (NGT: 1.43 6 0.07, 2.03 6 0.12 and 1.80 6 0.12,
respectively; IGT: 1.65 6 0.11, 2.46 6 0.12** and 1.94 6 0.08*, respectively; DM: 1.73 6
0.07, 2.34 6 0.08** and 2.47 6 0.09** nmol/ml, respectively; *p , 0.05 vs. fasting, **p , 0.01
vs. fasting). Glucose loading did not change nitrite/nitrate concentration in any of the groups.
CONCLUSIONS Hyperglycemia in response to oral glucose loading rapidly suppresses endothelium-dependent
vasodilation, probably through increased production of oxygen-derived free radicals. These
findings strongly suggest that prolonged and repeated post-prandial hyperglycemia may play
an important role in the development and progression of atherosclerosis. (J Am Coll Cardiol
1999;34:146–54) © 1999 by the American College of Cardiology
Diabetes mellitus (DM) is one of the most common chronic
diseases (1), and the predominant clinical form is Type 2
(non–insulin-dependent), which accounts for more than
90% of all cases (1,2). Most Type 2 diabetes is preceded by
a symptom-free period of impaired glucose tolerance (IGT),
which is characterized by a response to oral glucose load that
is abnormal but does not satisfy the criteria for diabetes (1).
Atherosclerosis, the main cause of coronary heart disease,
occurs with higher than normal frequency in patients with
diabetes and pre-diabetes, and is the major cause of mor-
bidity and mortality in diabetic patients (1–4). However,
the mechanism of the increased risk for atherosclerosis in
diabetes is still controversial (2–6). The response-to-injury
hypothesis of atherosclerosis states that the injurious re-
sponses initially occur to endothelium of the artery, leading
to endothelial dysfunction (7). Indeed, endothelial dysfunc-
tion has been shown to occur in patients with diabetes
(6–9), and chronic hyperglycemia is implicated as a cause of
endothelial dysfunction (5,6,9–13). However, Type 2 dia-
betes and IGT are often associated with other risk factors,
such as dyslipidemia, hypertension and obesity, each of
which may cause endothelial dysfunction (1–3,5,14).
Furthermore, in many of these patients, fasting blood
glucose may be within normal limits, and hyperglycemia
occurs only post-prandially. Thus, the precise role of hyper-
glycemia in the genesis of endothelial dysfunction in Type 2
diabetes and IGT remains to be elucidated. Recently,
noninvasive assessment of endothelial function of the bra-
chial artery has been performed by measuring flow-
mediated dilation (FMD) during reactive hyperemia with
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ultrasound technique (15–19). The purpose of the present
study was to examine whether endothelial dysfunction
occurs when acute hyperglycemia is induced during oral
glucose tolerance test (OGTT) in patients with Type 2
diabetes and in those with IGT by measuring FMD of the
brachial artery. We also measured plasma levels of thiobar-
bituric acid reactive substances (TBARS) as a marker of
lipid peroxide (20), and the serum levels of nitrite/nitrate as
metabolites of nitric oxide (NO) (21), the endothelium-
derived relaxing factor. These levels were compared with the
degree of the endothelium-dependent vasodilation in the
patients.
METHODS
Study subjects. The study group comprised 58 patients
(mean age, 57.8 6 1.0 years) who were admitted in our
hospital to examine coronary artery disease. All study
subjects were under 70 years old, and none of them had been
previously diagnosed with DM. All female subjects were
postmenopausal. None had had congestive heart failure.
None was receiving any kinds of drugs including hormones
from at least seven days before the study. Fasting glucose
levels of all the patients were ,140 mg/dl, and a 75-g
OGTT was performed to examine their risk factors for
coronary artery disease. Both IGT and DM were diagnosed
according to World Health Organization criteria (1).
Twenty-four patients had IGT, 17 had Type 2 DM and 17
had normal glucose tolerance (NGT). The characteristics of
the patients are shown in Table 1. Written informed
consent was obtained from each patient before the study was
commenced. The procedures used in the study were ap-
proved by the ethics committee at our institution.
Study design. We performed the present study during a
75-g OGTT to examine risk factors for coronary artery
disease. In a fasting state, 1- and 2-h after the administra-
tion of a 75-g glucose equivalent load (Trelan-G, Takeda,
Japan), FMD of the brachial artery was measured by two
skillful examiners. Successively, the subjects lay quietly for
15 min. Then, sublingual nitroglycerin (0.3 mg) was ad-
ministered, and 3 min later, the last measurements were
performed. Response to nitroglycerin was used as a measure
of endothelium-independent vasodilation. We excluded in-
dividuals with inadequate scan quality in either brachial
artery before the start of the study. All studies were
performed in a quiet and temperature-controlled room
(22°C to 23°C).
Vasodilation responses of the brachial arteries were mea-
sured by the ultrasound technique. The validity of this
method has been confirmed in our previous studies and by
others (15–19). Briefly, the diameter of the brachial artery
was measured from B-mode ultrasound images using a
7.5-MHz linear array transducer (SSH-160A, Toshiba,
Japan). Flow velocity in the brachial artery was measured
using a pulsed Doppler signal at a 70° angle to the vessel,
with the range gate (1.5 mm) in the center of the artery. The
brachial artery was scanned in the antecubital fossa in a
longitudinal fashion. Depth and gain settings were opti-
mized at the beginning of the study and were kept constant
throughout the recording period. When a satisfactory trans-
ducer position was found, the surface of the skin was
marked, and the arm remained in the same position
throughout the study. During the study, blood pressure was
monitored in the other arm every 2 min by an automated
blood pressure recorder.
Each subject lay quietly for 10 min before the first scan.
Abbreviations and Acronyms
ANOVA 5 analysis of variance
DM 5 diabetes mellitus
FMD 5 flow-mediated dilation
HDL 5 high-density lipoprotein
IGT 5 impaired glucose tolerance
LDL 5 low-density lipoprotein
NGT 5 normal glucose tolerance
NO 5 nitric oxide
OGTT 5 oral glucose tolerance test
TBARS 5 thiobarbituric acid reactive substances







Age (yrs) 52.6 6 1.8 58.5 6 1.6 62.2 6 1.2*
Men/Women 11/6 15/9 12/5
Body mass index (kg/m2) 22.5 6 0.3 23.9 6 0.3 25.2 6 0.4
Smoker 9 (52.9%) 15 (62.5%) 14 (82.4%)
Total cholesterol (mg/dl) 190.1 6 5.8 206.4 6 6.3* 216.8 6 5.4†
HDL cholesterol (mg/dl) 47.8 6 1.0 43.2 6 1.1* 41.1 6 1.2†
LDL cholesterol (mg/dl) 115.2 6 5.7 132.8 6 5.7* 142.2 6 5.8†
Triglyceride (mg/dl) 135.6 6 5.0 152.1 6 4.7* 167.9 6 4.4†
Increase in diameter after nitroglycerin (%) 13.9 6 0.2 14.0 6 0.3 14.2 6 0.2
*p , 0.05 vs. NGT; †p , 0.01 vs. NGT. Data are expressed as mean 6 SE.
DM 5 diabetes mellitus; HDL 5 high-density lipoprotein; IGT 5 impaired glucose tolerance; LDL 5 low-density
lipoprotein; NGT 5 normal glucose tolerance.
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After baseline measurements of the diameter and the flow
velocity in the brachial artery, a blood pressure cuff placed
around the forearm was inflated with a pressure of 250 to
300 mm Hg and was released after 5 min. The measure-
ments of the diameter and the flow velocity were continu-
ously performed between the cuff inflation and after the cuff
deflation. The ultrasound images were recorded on a super-
VHS videocassette recorder (BR-S601M, Victor, Japan),
and the arterial diameter was measured at a fixed distance
from an anatomical marker with ultrasonic calipers by two
independent observers. They were blinded as to not only
whether the individual was in the NGT, IGT, or DM
group, but also whether the images had been acquired with
the patients in a fasting state, 1 or 2 h after the glucose
loading.
Measurements were taken from the anterior to the
posterior interface between the media and adventitia (“m”
line) at the end diastole, incident with the R wave on a
continuously recorded electrocardiogram (15–17,19,22).
The diameters at four cardiac cycles were analyzed for each
scan, and the measurements were averaged. Diameter mea-
surements for the reactive hyperemia were taken 45 to 90 s
after the cuff deflation to measure peak diameter (17).
Responses of the vessel diameters to the reactive hyperemia
and nitroglycerin were expressed as the percentage increase
to the baseline value of the diameter. Blood flow was
calculated by multiplying the velocity-time integral of the
Doppler flow signal by heart rate and the vessel cross-
sectional area. The increase in the blood flow was calculated
by dividing the maximum flow within the first 15 s after the
cuff deflation by the flow at baseline (15–17).
In our study, the inter-observer variability for the re-
peated measurements of resting arterial diameter was
0.05 6 0.02 mm. The intra-observer variability for the
repeated measurements of resting arterial diameter was
0.02 6 0.02 mm. In a preliminary study, when these pro-
cedures were performed at the same time on two different
days in 20 volunteers, the average intra-subject test-retest
difference for the measurements of the arterial diameter
during the reactive hyperemia was 0.05 6 0.04 mm.
Blood sampling and assays. Blood specimens were ob-
tained after a 12- to 14-h fast, and second and third
specimens were obtained at 1- and 2-h after the glucose
loading. The plasma glucose concentration was determined
with an autoanalyzer using a glucose oxidase method. The
serum insulin concentration was measured by immunora-
diometric assay using an antihuman insulin antibody. The
serum total cholesterol and triglyceride concentrations in
the fasting state were measured enzymatically, and the
serum high-density lipoprotein (HDL) cholesterol concen-
tration was measured by heparin-Ca21/Ni21 precipitation
(15,23). Nitrite/nitrate, stable metabolites of NO, were
measured using an autoanalyzer (TCI-NOX1000, Tokyo
Kasei Kogyo, Japan), by a method based on the Griess
reaction (15,21,24). Briefly, the samples were passed
through a column containing copper-coated cadmium,
which reduces all nitrate to nitrite. The nitrite was then
detected when it reacted with Griess reagent (24). Absor-
bance was measured at 540 nm using a spectrophotometer
(15). The plasma lipid peroxide content was determined
using TBARS as markers (16,20). Briefly, 2.0 ml of trichlo-
roacetic acid-thiobarbituric acid-HCl reagent was added to
1.0 ml of sample and vortexed. To minimize peroxidation
during the assay procedure, butylated hydroxytoluene was
added to the thiobarbituric acid reagent mixture. Results
were expressed as malondialdehyde equivalent content
(nmol MDA/ml plasma).
Statistical analysis. Comparisons of data among the three
groups were performed using one-way analysis of variance
(ANOVA) followed by Bonferroni multiple comparison
test. The chi-square test was used to compare the prevalence
of smokers. The changes in variables were assessed by
two-way ANOVA with repeated measures followed by post
hoc testing with the Scheffe’s test. Correlations between
plasma glucose levels and FMD, between plasma glucose
levels and plasma TBARS levels, between plasma TBARS
levels and FMD, and between serum insulin levels and
FMD were examined using linear regression analysis. Sta-
tistical significance was defined as p , 0.05.
RESULTS
The serum levels of total cholesterol, low-density lipopro-
tein (LDL) cholesterol and triglyceride were higher, and
those of HDL cholesterol were lower in the IGT group and
the DM group than in the NGT group (Table 1). Body
mass index, mean age, and mean blood pressure tended to
increase as glucose tolerance deteriorated from IGT to DM
(Tables 1 and 2). The endothelium-independent vasodila-
tion, as assessed by arterial dilation to nitroglycerin, was not
different among the three groups (Table 1). The adminis-
tration of a 75-g glucose equivalent load did not elicit any
changes in the basal arterial diameter or the increase in
blood flow during the reactive hyperemia in any group
(Table 3). Heart rate, blood pressure and basal blood flow
tended to increase after the oral glucose loading (Tables 2
and 3). However, the differences are not significant.
Table 2 shows the plasma glucose, the serum insulin and
the serum triglyceride levels before and after oral glucose
loading among the three groups. In the fasting state, both
the plasma glucose and the serum insulin levels tended to
increase as glucose tolerance deteriorated from IGT to DM,
and there was a significant difference in the plasma glucose
and the serum insulin levels between the DM group and the
NGT group (p , 0.01). After the glucose loading, both the
plasma glucose and the serum insulin levels increased
markedly in each group. Plasma glucose levels were signif-
icantly higher in the IGT and the DM groups than in the
NGT group at both 1 and 2 h. The levels were not different
between the IGT group and the DM group at 1 h, but were
significantly higher in the DM group than in the IGT group
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at 2 h. Serum insulin levels were not significantly different
among the three groups at 1 h, but they were significantly
higher in the IGT group and the DM group than in the
NGT group at 2 h. There was no difference in the levels
between the IGT group and the DM group at 2 h. The
administration of a 75-g glucose equivalent load did not
elicit any changes in the serum triglyceride levels within
each group.
Table 2. Hemodynamic Data and Blood Sampling Data During Oral Glucose Tolerance Test
Fasting 1 h 2 h
NGT Group (n 5 17)
Heart rate (beats/min) 61.3 6 1.5 62.4 6 1.2 62.4 6 0.9
Mean blood pressure (mm Hg) 97.8 6 0.7 100.6 6 1.0 101.2 6 0.5
Plasma glucose levels (mg/dl) 90.5 6 1.4 153.5 6 6.3* 113.5 6 3.4*†
Serum insulin levels (mU/ml) 8.6 6 0.4 72.5 6 12.9* 38.8 6 5.1*†
Serum triglyceride levels (mg/dl) 135.6 6 5.0 137.4 6 4.4 134.1 6 4.3
IGT Group (n 5 24)
Heart rate (beats/min) 60.9 6 1.4 64.2 6 1.3 66.0 6 1.4
Mean blood pressure (mm Hg) 100.6 6 0.8 104.1 6 1.2 104.5 6 1.1
Plasma glucose levels (mg/dl) 105.3 6 2.8 220.2 6 5.2* 173.3 6 4.9*†
Serum insulin levels (mU/ml) 11.0 6 0.4 77.6 6 8.8* 81.4 6 6.3*
Serum triglyceride levels (mg/dl) 152.1 6 4.7 153.1 6 4.6 152.6 6 5.0
DM Group (n 5 17)
Heart rate (beats/min) 60.1 6 1.7 63.6 6 1.8 65.6 6 1.1
Mean blood pressure (mm Hg) 102.7 6 1.3 105.6 6 1.3 106.4 6 1.3
Plasma glucose levels (mg/dl) 128.4 6 1.1 239.6 6 8.8* 242.5 6 7.7*
Serum insulin levels (mU/ml) 14.0 6 0.9 79.4 6 9.1* 79.2 6 5.5*
Serum triglyceride levels (mg/dl) 167.9 6 4.4 169.9 6 4.2 167.5 6 4.3
*p , 0.005, vs. Fasting; †p , 0.01, vs. 1 h. Data are expressed as mean 6 SE.
DM 5 diabetes mellitus; IGT 5 impaired glucose tolerance; NGT 5 normal glucose tolerance.
Table 3. Brachial Arterial Data During Oral Glucose Tolerance Test
Fasting 1 h 2 h
NGT Group (n 5 17)
Baseline arterial diameter (mm) 3.72 6 0.11 3.73 6 0.10 3.74 6 0.10
Baseline blood flow (ml/min) 197.9 6 6.4 200.5 6 7.0 201.8 6 5.3
Increase in peak blood flow during
reactive hyperemia (%)
249.6 6 9.9 250.6 6 10.6 253.1 6 10.7
Flow-mediated dilation of brachial
artery (%)
7.53 6 0.40 4.24 6 0.28 6.35 6 0.40
IGT group (n 5 24)
Baseline arterial diameter (mm) 3.66 6 0.09 3.67 6 0.09 3.69 6 0.10
Baseline blood flow (ml/min) 198.8 6 4.3 205.6 6 5.3 206.9 6 5.3
Increase in peak blood flow during
reactive hyperemia (%)
257.0 6 9.6 254.5 6 10.5 256.5 6 10.4
Flow-mediated dilation of brachial
artery (%)
6.50 6 0.48 1.40 6 0.41† 4.00 6 0.47*‡
DM Group (n 5 17)
Baseline arterial diameter (mm) 3.67 6 0.11 3.74 6 0.10 3.73 6 0.11
Baseline blood flow (ml/min) 199.2 6 4.6 204.6 6 7.1 206.6 6 5.2
Increase in peak blood flow during
reactive hyperemia (%)
265.4 6 8.8 249.9 6 10.8 253.6 6 10.6
Flow-mediated dilation of brachial
artery (%)
4.77 6 0.37 1.35 6 0.38† 1.29 6 0.29†
*p , 0.01, vs. Fasting; †p , 0.005, vs. Fasting; ‡p , 0.01, vs. 1 h. Data are expressed as mean 6 SE.
DM 5 diabetes mellitus; IGT 5 impaired glucose tolerance; NGT 5 normal glucose tolerance.
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Figure 1 and Table 3 show the flow-mediated
endothelium-dependent vasodilation in response to oral
glucose loading in the three groups. Flow-mediated dilation
was diminished at 1 h in the IGT group, and it tended to
increase toward baseline levels at 2 h but was still lower than
the fasting levels. In the NGT group, FMD also tended to
decrease at 1 h after the glucose loading and returned to the
baseline levels at 2 h. Conversely, in the DM group, FMD
was diminished at 1 h and remained diminished at similar
levels at 2 h. There was a significant difference in the effect
of the glucose loading on FMD among the three groups
(p , 0.01, by ANOVA).
Figure 2 compares FMD in response to glucose loading
among the three groups. In the fasting state, FMD tended
to decrease as glucose tolerance deteriorated from IGT to
DM, and there was a significant difference in the degree of
FMD between the DM group and the NGT group (p ,
0.01). At 1 h, FMD was more reduced in both the IGT and
the DM group than in the NGT group (p , 0.01). There
was no difference in the degree of reduction between the
IGT group and the DM group. At 2 h, FMD was highest
in the NGT group and was lowest in the DM group (p ,
0.05, IGT vs. NGT and DM; p , 0.01, NGT vs. DM).
Figure 3 shows the plasma levels of TBARS in response
to glucose loading in the three groups. In the NGT group,
the plasma TBARS levels tended to increase at 1 h and to
decrease toward the fasting levels at 2 h after the glucose
loading. However, this was not significant (1.43 6 0.07,
2.03 6 0.12 and 1.80 6 0.12 nmol/ml, in fasting, at 1 and
2 h, respectively). The levels were increased at 1 h and were
decreased but still higher than the fasting levels at 2 h in the
IGT group (1.65 6 0.11, 2.46 6 0.12**, and 1.94 6 0.08*
nmol/ml, respectively: *p , 0.05 vs. fasting, **p , 0.01, vs.
fasting). In the DM group, the levels were increased at 1 h
and remained increased at 2 h (1.73 6 0.07, 2.34 6 0.08*,
and 2.47 6 0.09* nmol/ml, respectively: *p , 0.01, vs.
fasting). There was a significant difference in the effect of
the glucose loading on the plasma TBARS levels among the
three groups (p , 0.01 by ANOVA).
Figure 4 compares the plasma TBARS levels in response
to glucose loading among the three groups. In the fasting
Figure 1. Effects of oral glucose loading on the flow-mediated
dilation (FMD) of the brachial artery. There was a significant
difference in FMD among the three groups (p , 0.01, by
ANOVA). DM: diabetes mellitus; IGT: impaired glucose toler-
ance; NGT: normal glucose tolerance. Data are expressed as
mean 6 SE. *p , 0.01, versus fasting; **p , 0.005, versus fasting;
†p , 0.01, versus 1 h.
Figure 2. Comparison of the flow-mediated dilation of the bra-
chial artery in the fasting state, 1 and 2 h after oral glucose loading
among the three groups. DM: diabetes mellitus; IGT: impaired
glucose tolerance; NGT: normal glucose tolerance. Data are
expressed as mean 6 SE.
Figure 3. Effects of oral glucose loading on plasma TBARS levels.
There was a significant difference in the plasma TBARS levels
among the three groups (p , 0.01 by ANOVA). DM: diabetes
mellitus; IGT: impaired glucose tolerance; NGT: normal glucose
tolerance; TBARS: thiobarbituric acid reactive substances. Data
are expressed as mean 6 SE. *p , 0.05, versus fasting; **p , 0.01,
versus fasting; †p , 0.05, versus 1 h.
150 Kawano et al. JACC Vol. 34, No. 1, 1999
Endothelial Dysfunction in Hyperglycemia July 1999:146–54
state, no differences existed in the levels among the three
groups. At 1 h, the levels were higher in both the IGT
group and the DM group than in the NGT group (p ,
0.05, NGT vs. IGT and DM), and no significant difference
occurred in the levels between the IGT group and the DM
group. In contrast, at 2 h, the levels in the IGT group were
comparable to those in the NGT group, whereas the levels
were higher in the DM group than in the NGT and the
IGT groups (p , 0.05, DM vs. NGT and IGT).
No differences were seen in the serum levels of nitrite/
nitrate among the three groups in the fasting state. The
glucose loading did not significantly change the levels in any
of the groups (NGT, 66.57 6 5.52, 65.62 6 3.40, and
62.55 6 3.11 mmol/liter, in fasting, at 1 and 2 h, respec-
tively: NS; IGT, 67.66 6 4.73, 64.97 6 4.37 and 62.67 6
4.12 mmol/liter, respectively: NS; DM, 67.30 6 5.57,
65.52 6 5.44 and 64.25 6 5.80 mmol/liter, respectively:
NS).
The plasma glucose levels showed a significant negative
correlation with FMD (r 5 20.61, p , 0.01) and a
significant positive correlation with plasma TBARS levels
(r 5 0.62, p , 0.01), (Fig. 5 and 6). There was also a
significant correlation in FMD and plasma TBARS levels
(r 5 20.58, p , 0.01). In contrast, there was no significant
correlation between FMD and serum insulin levels.
DISCUSSION
There is widespread agreement that diabetes increases the
risk of coronary heart disease (1–4). However, the mecha-
nism of this increased risk is controversial (2–6,25). Con-
versely, Type 2 diabetes and IGT are commonly associated
with other risk factors, such as dyslipidemia, hypertension
and obesity (1–5,14). This was also shown in this study:
Total cholesterol, LDL cholesterol and triglyceride levels
were higher, HDL cholesterol was lower and blood pres-
sure, body mass index and prevalence of smokers tended to
increase in the DM and the IGT groups compared with the
NGT group. These risk factors may explain the reason why
the flow-mediated endothelium-dependent vasodilation in
the fasting state was reduced in the IGT group and the DM
group as compared with the NGT group.
Hyperglycemia may have a specific role in the increased
risk for atherosclerosis in patients with diabetes and IGT
(12,26). Although hyperglycemia is clearly related to dia-
betic microvascular complications (12), its contribution to
Figure 4. Comparison of plasma TBARS levels in the fasting
state, 1 and 2 h after oral glucose loading among the three groups.
DM: diabetes mellitus; IGT: impaired glucose tolerance; NGT:
normal glucose tolerance; TBARS: thiobarbituric acid reactive
substances. Data are expressed as mean 6 SE.
Figure 5. Correlation between the flow-mediated dilation of the
brachial artery and the plasma glucose levels. There was a signif-
icant negative correlation between them.
Figure 6. Correlation between the plasma TBARS levels and the
plasma glucose levels. There was a significant positive correlation
between them. TBARS: thiobarbituric acid reactive substances.
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increased risk for atherosclerosis in Type 2 diabetes remains
controversial.
Despite the lack of data to support a relationship between
the degree of hyperglycemia and the occurrence of coronary
heart disease in Type 2 diabetes, there is evidence for an
association between glycemia and coronary heart disease in
populations in which most people are not diabetic (2,27).
Nathan and co-workers suggested that risk for coronary
heart disease in patients with glucose intolerance may be
continuous and graded as other risk factors, such as lipids or
blood pressure (2,3). The recent 20-year follow-up for the
Whitehall Study, the Paris Study and the Helsinki Police-
men Study also supports this concept (28).
The changes of endothelial function after glucose load-
ing. The present study showed, for the first time, that the
flow-mediated endothelium-dependent vasodilation of the
brachial artery was rapidly reduced after glucose loading and
that a significant negative correlation occurred between the
flow-mediated endothelium-dependent vasodilation and
the plasma glucose levels in humans. These results indicate
that an elevated glucose concentration rapidly induces en-
dothelial dysfunction and are in agreement with those of the
previous in vitro and ex vivo studies in other species (29,30).
It is worth noting that, even in the NGT subjects and the
IGT patients whose fasting plasma glucose levels were
within normal limits, the endothelium-dependent vasodila-
tion was rapidly impaired in response to glucose loading.
Endothelial function returned to the baseline levels after 2 h
in the NGT group, but remained reduced in the IGT group
and the DM group (in the latter more severely). Thus, it is
possible that prolonged and repeated exposure to post-
prandial hyperglycemia may play an important role in the
development and acceleration of atherosclerosis, even in
those who have normal fasting plasma glucose levels. This
supports the idea proposed by Nathan and his co-workers
regarding the risk of glycemia for atherosclerosis (2,3).
Possible mechanisms of endothelial dysfunction after
glucose loading. Endothelium-dependent vasodilation has
been shown to be mediated by the endothelium-derived
relaxing factors, which are now identified as NO (21).
Previous studies have established that oxygen-derived free
radicals interfere with or destroy endothelium-dependent
vasodilation by inactivating NO in normal vessels (31,32).
In the present study, the endothelium-dependent vasodila-
tion of the brachial conduit artery decreased in association
with an increase in plasma levels of TBARS, a marker of
oxygen-derived free radicals. In contrast, the serum levels of
nitrite/nitrate, the metabolites and the marker for produc-
tion of NO (21) did not change in any of the groups after
the glucose loading. Because the nitrite/nitrate concentra-
tion includes the oxidative products of NO (33), hypergly-
cemia rapidly suppresses the endothelium-dependent vaso-
dilation, probably through an increase of oxygen-derived
free radicals, and results in a quenching of NO, and not
through a decrease of production/release of NO. This is in
agreement with the results in vitro studies by previous
workers (9,29,30,34). Changes of the serum triglyceride
levels after a meal also affect FMD of the brachial artery
(19). However, there were no changes in the serum triglyc-
eride levels throughout OGTT in any of the groups in the
present study.
The sources of oxygen-derived free radicals during acute
hyperglycemia may include a variety of mechanisms (35–
37). These include autoxidation, the nonenzymatic glyca-
tion of proteins due to extended exposure to hyperglycemia,
the metabolism of glucose via aldose reductase with changes
in sorbitol-myoinositol concentrations and the increased de
novo synthesis of diacylglycerol from glycolytic intermedi-
ates and subsequent activation of the protein kinase C
pathway (36,37). However, nonenzymatic glycation pro-
cesses do not account for the rapid increase of oxidative
products in response to acute hyperglycemia because the
glycation processes occur slowly over days to weeks (11).
Hyperinsulinemia and insulin resistance have been shown
to be risk factors for atherosclerosis (38,39), and the serum
levels of insulin increased in response to glucose loading in
this study. However, the increased insulin after the glucose
loading probably may not play an important role in the acute
induction of the endothelial dysfunction in the present
study; this is because there was no significant relationship
between FMD and the serum insulin levels. Insulin causes
endothelium-dependent vasodilation by releasing NO
(40,41), and this action may be impaired in the presence of
hyperglycemia.
Clinical implications. Endothelium-derived NO inhibits
platelet aggregation and development of atherosclerosis
(21). Impairment of the endothelium-dependent vasodila-
tion has been shown to be related to the pathophysiology of
vascular diseases (42). The increased concentrations of
oxygen-derived free radicals associated with elevated glucose
level indicate failure in protective mechanisms. A close
relationship was recognized between the magnitude of the
endothelium-dependent vasodilation in the coronary arter-
ies and that in the brachial arteries (16,18). The present
results suggest that the increased oxidative stress during
exposure to elevated glucose plays an important role in the
morbidity/mortality of the cardiovascular disease as any
other known risk factors for atherosclerosis (7).
Reactive hyperemia after temporary interruption of the
blood flow may result from an interplay between physical
(myogenic) and local metabolic factors, including prosta-
glandins and adenosine (43,44). Increased wall shear stress
owing to an increase in the blood flow results in the
production of the endothelium-derived NO (45,46). We
have demonstrated that after transient arterial occlusion,
NO plays a major role in the duration of hyperemia or flow
debt repayment but not in the peak reactive hyperemia (47).
In fact, local administration of the NO synthase inhibitor
NG-monomethyl-L-arginine did not affect the peak increase
in blood flow during the reactive hyperemia in human
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peripheral conduit arteries (48). This may explain why the
comparable increases were observed in the peak blood flow
among the three groups, irrespective of the differences in the
FMD during OGTT.
Study limitations. In the present study, patients were
hospitalized at our institution so we could examine coronary
artery disease. Thus, there were more patients with IGT and
those with DM as compared with the general population.
The principal finding of the present study was the
decrease in the flow-mediated endothelium-dependent va-
sodilation after glucose loading. Because FMD was affected
by the size of the baseline arterial diameter, each patient
rested on a bed during the study to exclude its effect. In fact,
in each group, the size of the baseline arterial diameter did
not change before and after the glucose loading. In contrast,
a slight increase occurred in the heart rate, blood pressure
and baseline blood flow after the oral glucose loading. This
may be due to increase of cardiac output and its redistribu-
tion to other tissue regions such as splanchnic bed.
The measurements of nitrite/nitrate and TBARS are
influenced by smoke, food, hormonal status and drugs
(15,16,21,49). To exclude their effects, we studied men and
postmenopausal women after 12- to 14-h fast, all of whom
did not smoke or receive any type of drugs from at least
seven days before the study.
Conclusions. Finally, hyperglycemia in response to oral
glucose loading rapidly suppresses endothelium-dependent
vasodilation, probably through an increased production of
oxygen-derived free radicals in humans. These findings
strongly suggest that prolonged and repeated post-prandial
hyperglycemia may play an important role in the develop-
ment and progression of atherosclerosis.
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